Hill-Rom (HRC) Issues Earnings Results

Hill-Rom (NYSE:HRC) posted its quarterly earnings data on Friday. The medical technology company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.13, Bloomberg Earnings reports. The company had revenue of $669.70 million during the quarter, compared to analysts’ expectations of $670.00 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.75 EPS. Hill-Rom updated its Q2 guidance to $1.00-1.02 EPS and its FY18 guidance to $4.57-4.65 EPS.

Hill-Rom (NYSE:HRC) opened at $89.00 on Friday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. Hill-Rom has a 12-month low of $57.18 and a 12-month high of $91.11. The company has a market cap of $5,947.97, a PE ratio of 44.72, a PEG ratio of 1.59 and a beta of 1.19.

The business also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 15th were given a dividend of $0.18 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.81%. Hill-Rom’s payout ratio is 36.18%.

A number of equities analysts have weighed in on the stock. KeyCorp reissued a “buy” rating and issued a $97.00 price objective on shares of Hill-Rom in a research report on Thursday, January 18th. Barclays reissued a “buy” rating and issued a $100.00 price objective on shares of Hill-Rom in a research report on Wednesday, January 10th. Zacks Investment Research raised shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a research report on Thursday, January 18th. Needham & Company LLC reissued a “buy” rating and issued a $105.00 price objective (up from $90.00) on shares of Hill-Rom in a research report on Tuesday, January 16th. Finally, ValuEngine cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $95.38.

In other news, CEO John J. Greisch sold 100,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the transaction, the chief executive officer now owns 230,851 shares of the company’s stock, valued at $19,119,079.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John J. Greisch sold 125,241 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the transaction, the chief executive officer now directly owns 280,851 shares in the company, valued at approximately $23,195,484.09. The disclosure for this sale can be found here. Insiders have sold 226,241 shares of company stock worth $18,708,644 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in Hill-Rom by 2.7% during the second quarter. State Street Corp now owns 1,681,107 shares of the medical technology company’s stock worth $133,831,000 after acquiring an additional 43,645 shares during the period. Principal Financial Group Inc. raised its stake in Hill-Rom by 8.5% during the third quarter. Principal Financial Group Inc. now owns 283,290 shares of the medical technology company’s stock worth $20,963,000 after acquiring an additional 22,188 shares during the period. Fred Alger Management Inc. raised its stake in Hill-Rom by 163.3% during the second quarter. Fred Alger Management Inc. now owns 9,217 shares of the medical technology company’s stock worth $734,000 after acquiring an additional 5,717 shares during the period. Magnetar Financial LLC raised its stake in Hill-Rom by 24.4% during the third quarter. Magnetar Financial LLC now owns 17,458 shares of the medical technology company’s stock worth $1,292,000 after acquiring an additional 3,421 shares during the period. Finally, Rhumbline Advisers raised its stake in Hill-Rom by 10.1% during the third quarter. Rhumbline Advisers now owns 141,115 shares of the medical technology company’s stock worth $10,443,000 after acquiring an additional 12,976 shares during the period. Hedge funds and other institutional investors own 82.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2018/01/26/hill-rom-hrc-issues-earnings-results.html.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Earnings History for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit